Stock Ratings / Health Care / SLGL / insiders

KROS (66) PYXS (29) SIGA (72) BBOT (37) ⌘ Pro Terminal →

Sol-Gel Technologies Ltd. (SLGL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$68.35 -0.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $68.16

Sol-Gel Technologies Ltd. (SLGL) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $224.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SLGL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SLGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $68.35 (-0.45% 1D, market cap $224.8M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SLGL ranks #247 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SLGL compare to KROS and PYXS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLGL carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M) and PYXS (Pyxis Oncology Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $226.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SLGL?

▼

Per SLGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001684693), Sol-Gel Technologies Ltd. generated $19.4M in revenue (+68.0% YoY), -$6.1M in net income, and $275.0K in free cash flow against $29.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $68.17 (-0.27%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 1.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLGL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY SLGL SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)

Altman Z-Score 8.54 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 1.4% FCF Margin ($275.0K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$72.40-10.2% Next Q

Q2 (-2Q)

Grade C$64.98+7.2% Next Q

Q3 (-1Q)

Grade C$69.63-1.8% Next Q

Current

Grade D+$68.35-0.7% Hist 90D α

Trajectory: C+ (62) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLGL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLGL currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($68.78) and Max Pain ($71.77) forces dealer call-delta covering toward $102.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SLGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SLGL Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SLGL)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SLGL. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLGL)

✓Walkthrough of SLGL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SLGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.03%▼ DESCENDING CHANNEL

2026-11-02O $67.29H $68.35L $64.55C $68.35VOL 29.4K

RES: $74.40SUP: $53.03SMA50: $68.78SMA200: $74.02

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLGL Butterfly Map → + Track SLGL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +68.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SLGL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SLGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLGL)

Health Care Rank #247 of 1016 ⚔️ KROS vs SLGL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLGL vs. KROS, PYXS, SIGA, BBOT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sol-Gel Technologies Ltd. (SLGL) ranks #247 by composite RQD confidence (54/100, grade D+) and #562 by equity capitalization ($224.8M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with SLGL at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SLGL ACTIVE Sol-Gel Technologies Ltd.	D+	54/100	—	—	-35.0%	-0.45%	$224.8M	Benchmark Subject
KROS Keros Therapeutics Inc.	C+	66/100	—	—	85.0%	-2.82%	$225.2M	/kros-vs-slgl →
PYXS Pyxis Oncology Inc.	E	29/100	—	82.8%	-35.0%	-4.23%	$226.0M	/pyxs-vs-slgl →
SIGA SIGA Technologies Inc.	B	72/100	9.8x	68.6%	42.7%	-4.40%	$228.5M	/siga-vs-slgl →
BBOT BridgeBio Oncology Therapeutics Inc.	D-	37/100	—	—	-35.0%	-2.96%	$216.5M	/bbot-vs-slgl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001684693

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sol-Gel Technologies Ltd. (SLGL) reported GAAP revenue of $19.4M (+68.0% vs. FY2024 revenue of $11.5M , and +1147.6% cumulative change since FY2023) , GAAP net income of -$6.1M, operating cash flow of $322.0K, and free cash flow of $275.0K (+102.0% YoY). On the balance sheet, SLGL closed FY2025 with $29.9M in total assets against $0 in total debt (Altman Z-Score: 8.54, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$19.4M	-$6.1M	$322.0K	$275.0K	$29.9M	—
FY2024 (FY)	2024-12-31	$11.5M	-$10.6M	-$13.9M	-$13.9M	$35.8M	—
FY2023 (FY)	2023-12-31	$1.6M	-$27.2M	-$17.7M	-$17.7M	—	—

3. SLGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SLGL compare to KROS and PYXS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SLGL?

Where is SLGL trading relative to its 50-day, 200-day, and 52-week technical levels?

SLGL last traded at $68.35 (-0.45% on volume of 33,525 shares), positioning the stock -0.63% below its 50-day simple moving average ($68.78) and -7.66% below its 200-day simple moving average ($74.02). Across its 52-week range of $28.81 to $97.97, SLGL sits at the 57.2% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($59.81 to $76.89).

SLGL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SLGL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SLGL leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: SLGL RQD Cockpit SLGL 12M Forecast SLGL Earnings & Move SLGL Dividends & DRIP SLGL Insiders & 13F SLGL Whale Options SLGL Profit Sankey SLGL News & Why

ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SLGL — Sol-Gel Technologies Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:40:37Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SLGL scores 54 out of 100, a D+ grade labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine 13/20 (reflecting ROIC of -35% and FCF yield of 0.12%); Whale 13F Flow 9/20 (institutional accumulation and options positioning); Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 13/20 (Beta of 1.0 and sector sensitivity); and Forensic Balance Sheet 14/20 (Altman Z 8.54, Piotroski F 6/9, Debt/Equity 0.5). For a prospective investor, the weakest pillar is insider conviction, while the cash engine and macro-fit pillars also score in the lower range. The forensic balance sheet metrics are the relative strength within the rating: a high Altman Z and Debt/Equity of 0.5 indicate balance sheet resilience even as operating economics remain negative. Valuation tradeoffs cannot be fully assessed because P/E and EV/EBITDA are not available in source data; the stock's position within its 52-week range of $59.43 - $74.54 at a price of 68.66 is therefore the only valuation reference available.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$19.4M	$-7.5M	$-6.1M	N/A	$0.3M	$11.0M	N/A
FY 2024	$11.5M	$-12.0M	$-10.6M	N/A	$-13.9M	$19.5M	N/A
FY 2023	$1.6M	$-29.3M	$-27.2M	N/A	$-17.7M	N/A	N/A

Per the SEC financials, revenue rose from $1.6M in FY 2023 to $19.4M in FY 2025 while operating losses narrowed from $-29.3M to $-7.5M. Per market data, the operating margin is -38.9%, the net margin is -31.6%, and gross margin is 0%. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 8.54 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. FY 2025 cash is $11.0M, down from $19.5M in FY 2024.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the catalysts are headline-level only, all tagged as market wire items: a Yahoo! Finance Canada stock page, a Seeking Alpha item referencing an Analyst/Investor Day slideshow dated 2026-10-15, a TradingView item reporting HC Wainwright & Co. reiterating a Buy rating with a $110 price target, an Investing.com item reporting HC Wainwright reiterating ahead of trial data, a Stock Titan item reporting a fund holding 166,473 shares exceeding 5% ownership, and a Yahoo Finance "New Strong Buy Stocks" listing. Risk watch items include the pending trial data referenced in the news and the negative margin profile. Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the company's products, customers, and revenue drivers, given that the source data does not describe them?
What is the outcome and timing of the trial data referenced in the news, and how would it affect revenue and cash?
What is the FY 2025 debt balance, since the source lists debt as N/A?
What is the basis for the weak insider conviction score, and what specific Form 4 or Congressional transactions drove it?
What is the EPS and valuation multiple profile, given that P/E, EV/EBITDA, and EPS are unavailable?

SLGL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sol-Gel Technologies Ltd. (SLGL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SLGL Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago

Sol-Gel Technologies Ltd. (SLGL) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 9h ago

Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day - Slideshow (NASDAQ:SLGL) 2026-10-15

Seeking Alpha report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 12h ago

HC Wainwright & Co. reiterates Buy rating on Sol-Gel Technologies, $110 price target

TradingView report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 15h ago

H.C. Wainwright reiterates Sol Gel stock rating ahead of trial data

Investing.com report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

A fund reports 166,473 shares in Sol-Gel Technologies (SLGL), exceeding 5% ownership.

Stock Titan report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 21h ago

New Strong Buy Stocks for October 16th

Yahoo Finance report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

SLGL - Phase 3 Gorlin Syndrome Catalyst Will Reshape Orphan Dermatology Outlook For This Business

Simply Wall St report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 1d ago

This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Benzinga report covering Sol-Gel Technologies Ltd. (SLGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SLGL Bull vs. Bear Conversation Board — What's Your Call at $68.35?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLGL 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $74.15 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SLGL (D+ • RQD 54/100) a Buy at $68.66?

Welcome to the SLGL (Sol-Gel Technologies Ltd.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $55.61 (-19.0%)

Spot @ $68.66

Pump the brakes on SLGL — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SLGL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Sol-Gel Technologies Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $83.77 (+22.0%)

Spot @ $68.66

SLGL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SLGL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $68.66 (52-wk range $59.43 - $74.54), any beat on forward guidance forces shorts and underweight funds to chase.